Brief: Statera Biopharma And Coeptis Therapeutics Announce Strategic Agreement For Rights To Entolimod

Statera Biopharma

13/04/2022 21:11

April 13 (Reuters) - Coeptis Therapeutics Inc  COEP.PK :
    * STATERA BIOPHARMA AND COEPTIS THERAPEUTICS ANNOUNCE
STRATEGIC
AGREEMENT FOR RIGHTS TO ENTOLIMOD
    * STATERA BIOPHARMA- UNDER TERMS OF DEFINITIVE AGREEMENT,
STATERA
WILL RECEIVE A $6 MILLION UPFRONT PAYMENT
    * STATERA BIOPHARMA- COEPTIS WILL ALSO ASSUME RESPONSIBILITY
FOR
ASSOCIATED LICENSES, AS WELL AS STATERA'S INTEREST IN GENOME
PROTECTION, INC
    * STATERA-TO RECEIVE REVENUE-BASED MILESTONE PAYMENTS FROM
COEPTIS
IN EXCHANGE FOR CO'S RIGHTS TO ANY PRODUCT CONTAINING ENTOLIMOD
AS ACTIVE INGREDIENT

Source text for Eikon:  ID:nGNX6tDnmL 
Further company coverage:  COEP.PK